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ABSTRACT:
Our understanding of breast cancer heterogeneity at the protein level is limited 
despite proteins being the ultimate effectors of cellular functions. We investigated the 
heterogeneity of breast cancer (41 primary tumors and 15 breast cancer cell lines) 
at the protein and phosphoprotein levels to identify activated oncogenic pathways 
and developing targeted therapeutic strategies. Heterogeneity was observed not only 
across histological subtypes, but also within subtypes. Tumors of the Triple negative 
breast cancer (TNBC) subtype distributed across four different clusters where one 
cluster (cluster ii) showed high deregulation of many proteins and phosphoproteins. 
The majority of TNBC cell lines, particularly mesenchymal lines, resembled the cluster 
ii TNBC tumors. Indeed, TNBC cell lines were more sensitive than non-TNBC cell 
lines when treated with targeted inhibitors selected based on upregulated pathways 
in cluster ii. In line with the enrichment of the upregulated pathways with onco-
clients of Hsp90, we found synergy in combining Hsp90 inhibitors with several 
kinase inhibitors, particularly Erk5 inhibitors. The combination of Erk5 and Hsp90 
inhibitors was effective in vitro and in vivo against TNBC leading to upregulation of 
pro-apoptotic effectors. Our studies contribute to proteomic profiling and improve 
our understanding of TNBC heterogeneity to provide therapeutic opportunities for 
this disease. 
INTRODUCTION
Gene expression profiling has contributed 
significantly to our understanding of breast cancer 
heterogeneity, biology and prognosis. Patterns of gene 
expression dissect the heterogeneity of breast cancer 
into five subtypes (luminal A, luminal B, basal-like, 
HER-2 and normal-like) that relate to histopathological 
parameters and immunophenotyping [1, 2]. More recently, 
integrative mutational and transcriptome profiling divides 
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breast cancer to ten subgroups with distinct clinical 
outcome [3]. In contrast, our understanding of breast 
cancer heterogeneity at the proteins level is limited despite 
proteins being the ultimate effectors of cellular functions.
Reverse phase protein arrays (RPPA) are widely 
used multiplexed arrays to study selected proteins in 
clinical specimens. RPPA in microdissected breast 
tumors recognized the classification of breast cancer to 
subgroups according to protein and phosphoprotein level 
[4]. The robustness of RPPA in non-microdissected breast 
tumors has been illustrated from technical perspectives; 
variability in tissue handling and intratumoral vs. 
intertumoral heterogeneity [5]. Importantly, Hennessy et al 
[5] demonstrated that RPPA can classify breast tumors to 
the same subtypes deduced from transcriptome profiling. 
Moreover, this study supported the use of RPPA in non-
microdissected breast tumors in the comprehensive cancer 
genome atlas (TCGA) study in breast cancer which also 
found proteome-based breast cancer subtypes which are 
highly concordant to transcriptome subtypes [6]. RPPA-
based proteomics have also succeeded in the identification 
of proteins and phosphoproteins which associate with the 
prognosis of breast cancer [7-9]. Unlike RPPA which is 
limited to 100 – 200 analytes, mass spectroscopy (MS)-
based proteomics can interrogate several hundreds of 
proteins. Indeed several studies used MS-based proteomics 
to identify biomarkers and targets for particular subtypes 
or disease progression and metastasis in breast cancer [10-
12]. However, due to the complex nature of this approach, 
limited studies use MS to investigate the heterogeneity of 
breast cancer [13, 14]. These two studies, using cell lines, 
again revealed that the proteome fingerprint classify breast 
cancer to subtypes similar to transcriptome classification.
Notably, although RPPA- and MS-based proteomic 
studies reveal concordance with transcriptome-based 
subtypes, these studies observed low correlation between 
protein and mRNA levels of their protein classifiers [5, 13, 
14]. This suggests that although the proteome fingerprint 
retains a similar classification of breast cancer to the 
transcriptome fingerprint, the proteome fingerprint is not 
identical and may not be predicted from mRNA levels. The 
lack of strong correlation between mRNA abundance and 
protein expression is not surprising since this relationship 
is not direct [15, 16], thus supporting the need for protein 
profiling.
In this article, we describe the profiling of protein 
levels and phosphorylation levels in aggressive/high grade 
primary breast tumors and established cell lines using the 
KinexTM antibody microarrays. The KinexTM antibody 
microarrays are as simple as RPPA technically but 
interrogate more than 400 kinases and kinase-associated 
proteins using validated antibodies [reviewed in 17]. The 
KinexTM antibody arrays have been used in several studies 
to compare cancer cell lines ([e.g. 18]). We focused on 
triple negative breast cancer (TNBC); a subtype associated 
with poor prognosis, and found that a subgroup in TNBC 
showed the highest and complex deregulation of proteins 
and phosphoproteins in comparison to hormone-positive 
tumors. We found that breast cancer cell lines recapitulate 
the patterns observed in the primary tumors. In our effort 
to functionally translate our finding, we identified TNBC 
cell lines to be sensitive to targeted inhibitors of several 
of the activated kinases we identified in patient samples. 
Finally, based on our findings, we rationalized the 
combination of Hsp90 and Erk5 inhibition as a therapeutic 
strategy against TNBC and demonstrated the efficacy of 
this combination in vitro and in vivo. 
RESULTS
Profiling of primary breast cancer tumors and cell 
lines with the KinexTM antibody arrays
The KinexTM KAM-1.3 antibody microarrays 
contain 812 probes (in duplicates; i.e. > 1624 spots) which 
investigate more than 400 kinases and kinase-associated 
proteins. We extracted protein from 41 fresh frozen 
primary breast tumors; 15 triple negative (TNBC), 15 
hormone positive (ER/PR-positive/HER2-negative) and 
11 HER2-positive tumors. These histological subgroups 
were similar in terms of median patient age, tumor size, 
histological grade and tumor cell content (Supplementary 
Table S1). Moreover, the correlation between the replicates 
of probes was higher than 0.85 for each tumor (Pearson’s 
correlation coefficient, Supplementary Table S1); 
illustrating the consistency of these arrays. Using all the 
probes in the KinexTM arrays and unsupervised hierarchal 
clustering, the primary tumors separated to several clusters 
(Supplementary Fig. S1A), illustrating the heterogeneity 
of breast cancer at the protein and phosphoprotein 
levels. At least six clusters were defined by the sample-
sample correlation plot shown in Fig.1A (clusters i – vi). 
Significance Analysis of Microarray (SAM) with a 1.75-
fold cutoff (Supplementary Fig. S1B) identified 349 
differentially expressed proteins and phosphoproteins 
between these six clusters (Fig.1B and Supplementary 
Table S2). TNBC tumors were heterogeneous where six 
TNBC tumors were in cluster ii along with one HER2-
positive tumor and three TNBC tumors were alone in 
cluster i. Cluster iii contained three TNBC tumors with six 
HER2-positive tumors and one ER/PR-positive tumor and 
the remaining three TNBC tumors clustered with one ER/
PR-positive tumors in cluster iv.  Clusters v consisted of 
five ER/PR-positive and four HER2-positive tumors and 
cluster vi of eight ER/PR-positive tumors. We also profiled 
15 breast cancer cell lines using the KinexTM KAM-1.3 
antibody microarrays and found that the 349 differentially 
expressed probes from the patient tumors generated three 
clusters in the breast cancer cell lines (Fig.1C). One cluster 
contained five TNBC cell lines while the remaining four 
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TNBC cell lines clustered with HER2-positive or ER-
positive cell lines. Of note, most of TNBC cell lines 
we tested, particularly the mesenchymal breast cancer 
cell lines (MDA-MB-436, MDA-MB-231, Hs578T and 
SUM159PT), resembled cluster ii in patients. We focused 
on cluster ii because it showed the highest deregulation of 
many probes compared to the other clusters and contained 
the largest number of TNBC primary tumors and TNBC 
cell lines.
Concordance of the KinexTM array results and the 
TCGA RPPA data
We analyzed the RPPA data (level 3 data) from the 
breast cancer TCGA study data [6] in the same way we 
analyzed our KinexTM antibody arrays. In agreement with 
our results, at least six clusters were defined by the sample-
sample correlation plot (Supplementary Fig. S2) using all 
the probes in the TCGA RPPA arrays (166 probes). TNBC 
Figure 1: The KinexTM antibody arrays confirm the heterogeneity of breast cancer. Lysates from fresh frozen primary, 
high grade, breast tumors prior to therapy were subjected to the KinexTM antibody arrays (Supplementary Fig. S1). (A) Sample-sample 
correlation plot using all the probes revealed six clusters (i – vi) which were compared by the SAM method and 1.75-fold change cutoff 
(Supplementary Fig. S1). (B) Hierarchal clustering of patient tumors based on the differentially expressed proteins/phosphoproteins. The 
numbers on the right of the heat map mark the 14 branches which differentiate the tumor clusters and these are annotated in Supplementary 
Table 2S. (C) Lysates from established breast cancer cell lines were also subjected to the KinexTM arrays. Hierarchal clustering of the breast 
cancer cell lines was supervised by the probes that were differentially expressed across the six clusters of primary patient tumors
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tumors were heterogeneous where 16/58 (28%) of TNBC 
tumors appeared in one cluster, 32/58 (55%) of TNBC 
tumors appeared in a second cluster and the remaining 
10/58 (17%) of TNBC tumors divided equally into two 
additional clusters (Supplementary Fig. S2). We compared 
the two main TNBC clusters to all other tumor clusters 
in the TCGA RPPA data and found that 65 probes that 
detect 61 proteins and phosphoproteins were deregulated 
Figure 2: Validation of phosphorylations of proteins identified in the KinexTM antibody arrays using the Proteome 
ProfilerTM antibody arrays. Lysates from four TNBC cell lines (MDA-MB-231, Hs.578T, BT549 and MDA-MB-435) and four luminal 
cell lines (MCF7, T47D, MDA-MB-175 and ZR751) were analyzed using the Proteome ProfilerTM Array for (A) human phospho-kinases 
and (B) human phospho-MAPK pathway. Bar graphs show the average ratio of TNBC/luminal normalized intensity for each phosphoprotein 
(±SEM, n = 4 cell lines each with two technical replicate for each phosphoprotein). Dashed lines mark the 1-fold (no change) and the 2-fold 
ratios and insets show representative arrays. Red bars: probes which validate exact phosphorylations in the KinexTM arrays. Orange bars: 
probes that identify additional phosphorylations of phosphoproteins to those identified in the KinexTM arrays. Blue bars: probes identifying 
phosphoproteins that were upregulated at the protein level in the KinexTM arrays. Black bars: probes that were not present in the KinexTM 
arrays or did not meet the cutoff criteria in analysis
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in these tumors (1.5-fold cutoff, Supplementary Table 
S3). Of these 61 proteins and phosphoproteins, 26 did 
not have probes to detect them in the KinexTM antibody 
arrays; therefore we were able to compare the concordance 
between our results and the TCGA RPPA data based 
on 35 proteins/phosphoproteins. Of these 35 proteins/
phosphoproteins in the TCGA RPPA, 24 (69%) were also 
deregulated in the TNBC clusters in our KinexTM arrays in 
the same direction (marked in Supplementary Table S3). 
The remaining 11 proteins/phosphoproteins in the TCGA 
RPPA results did not meet the threshold criteria in our 
study (7 proteins/phosphoproteins) or showed deregulation 
in the opposite direction (4 proteins/phosphoproteins). 
Thus, the heterogeneity and the clustering of breast cancer 
in general, and in TNBC specifically, could be replicated 
in the TCGA RPPA data which profiled more tumors. The 
advantage of the KinexTM antibody arrays however, resides 
in the larger coverage of proteins/phosphoproteins (812 
probes in the KinexTM arrays vs. 166 probes in the TCGA 
RPPA). Altogether, there is a high agreement between our 
results and those from TCGA RPPA data.
Validation of deregulated proteins and 
phosphoproteins in TNBC cluster ii
To validate the deregulated phosphoproteins 
discovered in cluster ii in the KinexTM arrays, we used 
independent small arrays, the Proteome ProfilerTM Arrays 
for human phospho-kinases and phospho-MAPK pathway 
(R&D Systems). We compared the phosphorylation 
levels in four TNBC cell lines (MDA-MB-231, Hs.578T, 
BT549 and MDA-MB-435) which resemble cluster ii 
in patients and four luminal cell lines (MCF7, T47D, 
MDA-MB-175 and ZR751) which resemble cluster vi 
(pure ER/PR-positive) patients. As shown in Fig.2 and 
Supplementary Table S2, the R&D arrays validated the 
upregulation of 18 phosphoantibodies in cluster ii (marked 
in red). Furthermore, the R&D arrays identified additional 
phosphorylation sites of 15 upregulated phosphoproteins in 
cluster ii in the KinexTM arrays (marked in orange in Fig.2 
and Supplementary Table S2). Moreover, 13 upregulated 
phosphoantibodies in the R&D arrays could be explained 
Figure 3: Pathway analysis of deregulated proteins and phosphoproteins in TNBC. Pathway analysis in IPA® using 
only direct protein-protein interaction data was used and the deregulated proteins/phosphoproteins in TNBC cluster ii identified three 
overlapping networks. These networks were merged and visualized (Supplementary Fig. S3). (A) Canonical signaling pathways using 
IPA® which were enriched (Fisher’s exact test p-value) in the deregulated proteins/phosphoproteins in TNBC cluster ii subgroup. (B) The 
upregulated phosphoproteins (marked with P) and proteins in cluster ii were analyzed using IPA® and a single network of direct protein-
protein interactions was identified. Shades of pink/red reflect the extent of upregulation. At least two nodes, MAPKs and HSPs, were clearly 
identified in the center of complex signaling cascades.
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by the upregulation of the total protein in the KinexTM 
arrays (marked in blue in Fig.2 and Supplementary Table 
S2). Finally, the R&D arrays detected the upregulation of 
phosphoproteins (marked in black in Fig.2) which were 
not present in the differentially expressed phosphoproteins 
in the KinexTM arrays. Some of these phosphoantibodies 
were not present in the KinexTM arrays while the remaining 
did not meet the cutoff criteria in the analysis. In summary, 
of the 59 upregulated (> 1.5-fold) phosphorylations in 
cluster ii vs. cluster vi in the KinexTM arrays, the R&D 
arrays contained antibodies against 18 phosphorylation 
sites and all validated.
Next, we used the Ingenuity Pathway Analysis 
(IPA®) software to determine networks and pathways 
that describe the protein-protein interactions (PPI) 
relationships between the deregulated proteins and 
phosphoproteins in cluster ii tumors compared to cluster 
vi tumors. Three overlapping networks were enriched in 
this analysis (Supplementary Fig. S3A) and were merged 
to obtain one network (Supplementary Fig. S3B). The 
canonical signaling pathways that were activated by the 
deregulation of proteins/phosphoproteins in the cluster ii 
subgroup are shown in Fig.3A. By analyzing the network 
of direct protein-protein interactions for upregulated 
proteins and phosphoproteins only, robust and cross-
talking signaling cascades from the plasma membrane to 
Figure 4: Targeted inhibition of activated kinases in cluster ii kills TNBC cell lines. (A) Activated cross-talking canonical 
signaling pathways in TNBC tumors in cluster ii. (B) Six TNBC cell lines, four non-TNBC cell lines and the “near-normal” MCF10A cell 
line were treated (in duplicates) with escalating doses of the specified drugs and survival was measured six days after treatment using the 
CellTitreTM assay. Data shown is -log
10
[IC50], a measure of sensitivity, where red color denotes relative increase in sensitivity. The red 
box marks drugs which specifically killed TNBC cell lines in comparison to non-TNBC cell lines. The raw data of dose response curves 
are shown in Supplementary Fig. S4. (C & D) Two Hsp90 inhibitors (PF04929113 and AUY922) were separately used as single agents or 
in combination with the specified kinase inhibitors. The combinations were performed using the IC25 of each drug against the specified 
TNBC cell lines. Data shown is the survival of cells where red color represents more killing than green color. Raw data for panels C and D 
are shown in Supplementary Fig. S5.
Oncotarget3151www.impactjournals.com/oncotarget
the nucleus were identified in cluster ii tumors (Fig.3B). 
At least two nodes, mitogen activated protein kinases 
(MAPKs) and heat shock proteins (HSPs) nodes, were 
at the center of these complex signaling cascades and 
pathways. 
Proteomic profiles may not be accurately 
predicted by transcriptome profiling
The phosphorylation of proteins may not be 
predicted by changes in mRNA levels; however, 
the upregulation of proteins may be associated with 
increased abundance of mRNA transcripts. To this end, 
we interrogated the OncomineTM database to determine 
whether the upregulated proteins in our screen were 
accompanied with elevated mRNA in TNBC. We 
analyzed two large patient datasets, the TCGA [6] and the 
METABRIC [3], and the Neve et al. breast cancer cell 
lines dataset [19], and found that only 9 of the 49 (18%) 
upregulated proteins we identified in TNBC had evidence 
for elevated mRNA levels (Supplementary Table S4). This 
poor protein-mRNA correlation was in agreement with 
Figure 5: The combination of Hsp90 inhibition and Erk5 inhibition is synergistic in TNBC. (A&B) Cultures of six TNBC 
cell lines were treated with escalating doses of ERK5i XMD 8-92 combined with Hsp90i PF-04929113 (A) or the Hsp90i AUY922 
(B) to calculate the combination index (CI, < 1 is synergistic) . (C) Graph of CI for the Hsp90 inhibitors at the lowest doses with Erk5 
inhibition. (D) Immunoblot analysis of MDA-MB-231 cells treated with 1 µM Erk5i (XMD 8-92 ) alone, 2 nM of Hsp90i (AUY922) alone, 
chemotherapy alone (2.5 nM docetaxel and 10 nM doxorubicin) or the combinations at 24 hours after treatment with indicated antibodies. 
(E) Clonogenic survival of MDA-MB-231 cells when subjected to treatments as indicated in D at 72 hours or 96 hours.
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previous proteomic-based profiling in breast cancer [5, 
13, 14]. Upon closer examination, we found that many 
of the activated kinases in our screen are oncoclients of 
the heat shock protein Hsp90; known to stabilize these 
proteins [20-22]; thus the elevation of proteins in cluster ii 
may be due to stabilization rather than elevation of mRNA 
levels. In agreement, the upregulation of Hsp90 protein 
was consistently detected in TNBC tumors and cell lines 
using 10 independent probes on the KinexTM arrays.
In vitro survival and growth after inhibition of 
signaling networks 
Based on the signaling cascades envisioned from the 
kinome profiling/pathway analysis above and outlined in 
Fig.4A, we compared the sensitivity of TNBC cell lines 
(MDA-MB-231, BT549, MDA-MB-436, Hs.578T, MDA-
MB-468 and BT20), non-TNBC cell lines (MCF7, T47D, 
ZR751 and BT474) and the “near-normal” MCF10A cell 
line to 24 small molecule inhibitors. Cell survival at six 
days after treatment showed that TNBC breast cancer cell 
lines were more sensitive than non-TNBC cell lines to 13 
drugs (Fig.4B and Supplementary Fig. S4). Given the high 
level of Hsp90 we identified and the role of this chaperon 
in oncogene activation, we investigated the combinations 
of the molecular inhibitors with Hsp90 inhibitors. Two 
different inhibitors of Hsp90 showed synergy in the 
killing of TNBC cell lines when combined with inhibitors 
targeting PAK1, FAK/PYK2, IGF-1R/IR, PKC, AKT/
p70S6K, GSK3, p38 MAPK, JNK, DNA-PK or Erk5 
(Fig. 4C&D and Supplementary Fig. S5). Particularly, 
Figure 6: The combination of Erk5 and Hsp90 inhibitors in vivo. Female nude mice bearing the TNBC MDA-MB-231 xenografts 
(50mm3 volume) were untreated (vehicle control) or treated with chemotherapy (chemo; 2 mg/kg docetaxel and 10 mg/kg doxorubicin 
administered i.p. on days 1 and 8). Additional groups of mice were treated with Erk5 inhibitor alone (Erk5i XMD 8-92 at 25 mg/kg) or 
Hsp90 inhibitor alone (Hsp90i AUY922 at 25 mg/kg) daily on days 1-5 and days 8-12. Additional groups of mice were treated with the 
combinations; chemo+Erk5i or Hsp90i+Erk5i. Six tumors were excised on day 13 (after treatment completion) for ex vivo studies. (A) 
Tumor growth curves based on change in tumor volume compared to day 0 prior to treatment (n=10 tumors/group). (B) Representative 
immunoblots from two tumors per group with indicated antibodies (cPARP1 – cleaved PARP1). Blots from additional four more tumors/
group showed similar results (Supplementary Fig. S7). (D&E) Representative images (20x magnification, scale bar 100 µm) of tumor 
histology (H&E and trichrome staining) and IHC staining for DNA double strand breaks (DSBs, γH2AX staining) and apoptosis (ApopTag) 
from control and Hsp90i+Erk5i treated mice on day 13. Quantification of staining from six tumors/group was performed as in Methods; (E) 
ApopTag staining, (F) γH2AX staining, (G) cellularity: ratio of pink (cells) to blue (collagen) staining from trichrome staining. Error bars 
represent the standard error of the mean, * p<0.05, ** p<0.01 and *** p<0.001 from One-Way ANOVA (GraphPad® Prism).
Oncotarget3153www.impactjournals.com/oncotarget
the combination of Hsp90 inhibition with Erk5 inhibition 
produced the highest and most consistent synergy amongst 
the six TNBC cell lines tested (Supplementary Fig. S5).
Erk5 as a therapeutic target in TNBC
We focused on the inhibition of Erk5 (MAPK7) 
since Erk5 is an attractive target for cancer therapy [23, 
24]. We confirmed the higher level of Erk5 in TNBC cell 
lines compared to non-TNBC cell lines (Supplementary 
Fig. S6). Activated Erk5 is not a client of Hsp90 [25] 
and the ERK5/Nrf2-mediated oxidative stress response 
pathway is activated while the ERK/MAPK signaling 
pathway is inhibited in response to Hsp90 inhibition 
[22]. Hsp90 inhibition in TNBC was shown to inhibit the 
phosphorylation of Erk1/2 and decrease the anti-apoptotic 
Bcl-xL protein [26]. Collectively, these observations are 
consistent with the synergy we observed when combining 
Erk5 inhibition with Hsp90 inhibition (Supplementary 
Fig. S6). To expand on this synergy, we investigated the 
combination of Erk5 inhibition with Hsp90 inhibition 
in cell killing across various doses. Indeed, low doses 
of Hsp90 inhibitors (Hsp90i) with the Erk5 inhibitor 
XMD 8-92 (Erk5i) showed strong synergy (Fig. 5A-C). 
Using these low doses, the phosphorylation of Erk5 was 
inhibited by the Erk5i and Hsp70 stabilization (surrogate 
marker for Hsp90 inhibition) was detected with the 
Hsp90i, confirming the specificity of these inhibitors 
(Fig.5D). The combination of Erk5i and Hsp90i or Erk5i 
with chemotherapy resulted in significant decrease in 
the phosphorylation of Erk1/2 and decrease in the anti-
apoptotic Bcl-xL protein (Fig.5D). This explained the 
significant decrease in clonogenic survival observed in 
these combinations (Fig.5E).
Based on our in vitro results, we investigated 
these combinations with Erk5 inhibitor in vivo using 
the MDA-MB-231 TNBC xenografts model. Tumors 
treated with Erk5i alone (XMD 8-92 at 25 mg/kg) or 
Hsp90i alone (AUY922 at 25 mg/kg) showed a moderate 
delay in tumor growth (Fig.6A). We confirmed the 
inhibition of Erk5 phosphorylation by the Erk5i and the 
stabilization of Hsp70 by the Hsp90i by immunoblots on 
tumor lysates prepared on day 13 after the completion 
of treatments (Fig.6B and Supplementary Fig. S7). 
While the combination of Erk5i with chemotherapy 
(docetaxel+doxorubicin) reduced tumor growth, the 
combination of Erk5i and Hsp90i showed a strong anti-
tumor response (Fig.6A). The latter combination was 
associated with prolonged apoptotic cell death as judged 
by the increase of pro-apoptotic Bcl family members 
Bim and Bak and the cleavage of PARP1 (Fig.6B and 
Supplementary Fig. S7) and ApopTag staining by IHC 
(Fig.6D&E). We also detected a significant increase in 
DNA double strand breaks (DSBs) detected by γH2AX 
staining (Fig.6F) and a significant reduction in tumor 
cellularity as measured by the ratio of cells to collagen 
in trichrome staining (Fig.6G). Collectively, our results 
confirm the synergy of the combination of Hsp90 and 
Erk5 inhibitors in vivo which could be explained by 
significant induction of apoptotic cell death and tumor 
tissue degeneration.
DISCUSSION
Proteomic profiling of high-grade breast cancers 
using the KinexTM antibody microarrays confirmed 
the heterogeneity of breast cancer in general with the 
identification of at least six subgroups. Particularly, 
TNBC is heterogeneous at the proteomic level where 
one subgroup of TNBC showed a wide spectrum of 
activated oncogenic signaling pathways in comparison 
to other TNBC tumors as well as non-TNBC subtypes. 
The activated signaling pathways we found in this 
TNBC subgroup (cluster ii) did not associate with 
increased mRNA expression in published gene expression 
microarray datasets. Our results, and others [5, 13, 14], 
revealed that the proteomic fingerprint classifies breast 
cancer to similar subtypes as transcriptome profiling; 
however, the two fingerprints are not identical.
The TNBC tumors in our proteomic study divided 
across four different tumor clusters with strong differences 
at the protein and phosphoprotein levels. Our finding is 
in line with previous studies reporting heterogeneity 
within TNBC. Immunophenotypically, TNBC can be at 
least divided into basal-like and non-basal like groups 
[27]. At the transcriptome level, while the majority (~ 
70%) of TNBC tumors are classified as basal-like, the 
remainder are spread across the other intrinsic subtypes; 
luminal A and B, Her2-enriched and normal-like [28]. 
The extent of TNBC heterogeneity has been further 
characterized by Lehmann et al. [29] in a study which 
identified six molecular subtypes of TNBC based on gene 
expression analysis. Similarly, we found that 9 out of 15 
(60%) TNBC tumors clustered together (clusters i and ii) 
whereas the rest (6 out of 15, 40%) were admixed with 
hormone-positive or HER2-positive tumors (clusters iii 
and iv) [5]. Similarly, we found that 9 out of 15 (60%) 
TNBC tumors clustered together (clusters i and ii) whereas 
the rest (6 out of 15, 40%) clustered closer to hormone-
positive or HER2-positive tumors (clusters iii and iv). In 
our study, the TNBC tumors in cluster ii were related to 
TNBC cell lines that are classified as mesenchymal- and 
mesenchymal-stem like at the transcriptome level [29]. 
These tumors and cell lines showed robust signaling 
cascades with cross-talking canonical signaling pathways 
some of which have been previously described as targets 
for TNBC such as ERK/MAPK [11], JAK/STAT signaling 
[30, 31] and PI3K/AKT/PTEN [32, 33].
In an effort to translate our findings into therapeutic 
strategies, we showed that TNBC cell lines were sensitive 
to several inhibitors which were selected based on the 
activated signaling pathways identified by proteomic 
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profiling. Similar differential responses of breast cancer 
cell lines, according to subtypes and/or pathways, to 
therapeutics have been previously reported [34]. Our 
study only shared three inhibitors with the previous 
study [34] which target MEK or EGFR and our results 
are in agreement that TNBC cell lines are more sensitive 
to these inhibitors than luminal breast cancer cell lines. 
The advantage of our study is that the selection of drugs 
was envisaged by proteomic characterization of pathway 
activation. Moreover, we identified synergistic effects 
when combining activated kinase inhibitors with inhibitors 
of the chaperone Hsp90. The heat shock protein Hsp90 
has been described as a therapeutic target in TNBC [26] 
and we recognized that not only Hsp90 was upregulated 
in TNBC tumors and cell lines in our study, but also that 
several of the activated kinases we identified are onco-
clients of Hsp90. We hypothesized that the inhibition 
of Hsp90 would lead to inhibition of several signaling 
pathways identified in our study and that the additional 
inhibition of specific pathway would lead to enhanced 
toxicity in TNBC cells. Indeed, we found the combined 
inhibition of Hsp90 and one of 11 other kinases was 
synergistic, particularly, the combination of Hsp90 and 
Erk5 inhibition.
We focused on Erk5 as a novel target in TNBC. 
Erk5 regulates the Nrf2 (NFE2L2) transcription factor 
[35] which was also upregulated in TNBC in our study. 
Activated Erk5 is not a client of Hsp90 [25] and the 
Erk5/Nrf2-mediated oxidative stress response pathway is 
activated in response to Hsp90 inhibition [22]. Erk5 has 
been suggested as a target for cancer therapy [23, 24]. 
Using breast cancer cell lines, studies showed that Erk5 
plays roles in cell proliferation by regulating cyclin D1 
and CDKs [36-38], epithelial mesenchymal transition 
[39], MET/HGF-induced migration [40, 41] and integrin/
FAK-mediated metastasis [42]. The MEK5-Erk5 pathway 
mediates progression to an ER-negative, mesenchymal 
and endocrine therapy resistant phenotype [43]. 
Experimentally, the knockdown of MEKK2-MEK5-Erk5 
pathway affects the primary tumor growth and metastasis 
in xenografts model of the TNBC cell line MDA-
MB-231 [44]. Clinically, Erk5 protein is overexpressed 
in early stage breast cancer and associated with disease 
free survival [45]. In a recent study [43], activated 
(phosphorylated) Erk5 was found in 77% of breast tumors 
in comparison to adjacent tissue. In our previous study of 
aggressive breast tumors which metastasized to the brain 
[46], we also found activated Erk5 in 78% of these tumors 
and more importantly, we found activated Erk5 in 100% 
of brain metastasis from breast tumors (p = 0.032 cf. 
78% in matched primary breast tumors [46]). Altogether, 
Erk5 is an attractive therapeutic target in breast cancer, 
particularly in TNBC. To our knowledge, we are the first 
to report targeting Erk5 using a molecular inhibitor in 
vivo in breast cancer. Our in vivo study demonstrated the 
utility of Erk5 inhibition as a therapeutic strategy alone 
or in combination with chemotherapy and more so when 
combined with Hsp90 inhibition in TNBC.
In conclusion, we report the first proteomic study 
of breast cancer using the KinexTM antibody arrays 
that can interrogate several hundred more proteins 
and phosphoproteins than RPPA and in a less complex 
fashion than mass spectroscopy-based proteomics. The 
proteomic-fingerprint from the KinexTM antibody arrays, 
similar to RPPA- and MS-based proteomics, identified 
subtypes within breast cancer that reflect transcriptome 
profiling; however, the proteomic- and transcriptome-
fingerprints were not necessarily identical. The more direct 
translational path of proteomic profiling for identifying 
therapeutic targets was illustrated by the identification 
of several inhibitors which affect the survival of the 
aggressive TNBC cell lines. Our in vivo studies support the 
notion that the inhibition of several oncogenic pathways 
is required for making an impact against TNBCs which 
exploit cross-talking pathways to drive their aggressive 
phenotype.
MATERIALS AND METHODS
Primary breast tumor collection and cell culture
The Brisbane Breast Bank collected fresh breast 
tumor samples from consenting patients; the study was 
approved by the local research ethics committees. Clinical, 
histopathological and the status for estrogen [ER] and 
progesterone [PR] receptors and HER2 were obtained 
from pathology reports (Supplementary Table S1). The 
cut off for ER and PR positivity was 1% and the HER2 
status was defined using the HercepTestTM (Dako). Breast 
cancer cell lines from ATCCTM (VA, USA) were cultured 
as per ATCCTM instruction and tested for mycoplasma and 
authenticated using STR profiling.
KinexTM antibody and Proteome ProfilerTM arrays
Fresh frozen primary breast tumors and fresh frozen 
cell lines were lysed using the KinexTM lysis buffer as 
per the manufacturer instructions (Kinexus Corporation, 
Vancouver, Canada). Dye-labeling of protein lysates, 
hybridization to the KinexTM antibody array (KAM-1.3 
Antibody Microarray) and signal intensity extraction were 
performed by Kinexus Corporation. Signal intensities for 
the 812 probes (in technical replicates), which included 
pan-specific antibodies for total proteins and phospho-
specific antibodies against specific phosphorylations, were 
analyzed using BRB-ArrayTools [47]. Signal intensities 
were quantile-normalized to perform unsupervised 
hierarchical clustering and Significance Analysis of 
Microarray (SAM). For the Proteome ProfilerTM arrays, 
lysates from cell lines were hybridized to the arrays and 
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phosphorylation levels were detected and quantified as per 
manufacturer instructions (R&D Systems, MN, USA).
Ingenuity pathway analysis and OncomineTM 
analysis
Pathway analysis was performed using the Ingenuity 
Pathway Analysis® (IPA) software (Ingenuity Systems®, 
Redwood City, CA) and we limited the analysis to 
direct protein-protein interactions only to identify 
signaling networks and canonical signaling pathways. 
The OncomineTM database [48] (Compendia Bioscience, 
Ann Arbor, MI), a large consortium of gene expression 
microarray datasets, was interrogated for the mRNA 
expression levels of proteins identified in our screen.
In vitro drug sensitivity screens
Small molecule inhibitors were purchased from 
Tocris Biosciences (R&D Systems): PF-4708671, 
U 73122, GSK2334470, IPA3, SL0101-1 and XMD 
8-92 or from Selleck Chemicals LLC (TX, USA): PF-
562271, Enzastaurin (LY317615), AUY922 (NVP-
AUY922), 17-AAG (Geldanamycin), PF-04929113 
(SNX-5422), AZD6244 (Selumetinib) , AT7867, CHIR-
98014, LY2228820, BIX 02188, AS703026, PH-797804, 
SP600125, NU7441. All inhibitors were prepaed in DMSO 
at 100 mM. Cells were treated with inhibitors prepared in 
culture media where the final concentration of DMSO was 
2% v/v. Vehicle control treatments consisted of culture 
media containing 2% v/v DMSO. Six days after treatment, 
cell survival was measured in comparison to vehicle 
controls using the CellTiter 96® Assay as per manufacturer 
instructions (MTS assay, Promega Corporation, WI, 
USA). Data were analyzed in GraphPad Prism® version 
5.00 for Windows (GraphPad Software, CA, USA) to 
measure the log
10
 of IC50 for each drug. For combination 
assays, drugs were added simultaneously. Heatmaps for 
sensitivities (-log
10
 of IC50) were prepared using D-chip 
Analyzer software [49]. 
In vivo models and treatments
The local animal ethics committee gave approval 
for use of the mice. Female balb/c nude mice at 5 weeks 
of age (Animal Resources Centre, WA, Australia) were 
inoculated in the mammary fat-pads with exponentially 
growing MDA-MB-231 TNBC cells (5x106 per fat pad) 
in 50 µL of 50:50 PBS:MatrigelTM (BD Biosciences, CA, 
USA). Treatments started when tumors were 50 ± 1 mm3 
as calculated from caliper measurement of tumor’s longest 
(a) and shortest (b) diameters: tumor volume (mm3) = a/2 
x b2. Docetaxel, doxorubicin and the Hsp90 inhibitor 
AUY922 were purchased from Selleck Chemicals and the 
Erk5 inhibitor XMD 8-92 from Tocris Biosciences. All 
drugs were diluted in 5% solution of D-glucose in PBS for 
intraperitoneal injection. Doses and schedule of treatments 
are detailed in Figure legends. Mice were monitored for 
change in weight and other toxicity indications and none 
were observed. Tumor growth was monitored by caliper 
measurements to calculate the change in tumor volume 
compared to day 0. Six tumors were excised on day 13 to 
perform ex vivo studies as below.
In vitro and ex vivo studies for the combination of 
Hsp90 and Erk5 inhibition
For the combination index studies in vitro, cultures 
of TNBC cell lines were left untreated or treated with 
escalating doses of the Erk5 inhibitor alone, Hsp90 
inhibitor alone or the combinations. After 6 days of 
treatment, the MTS assay was performed to measure 
survival in comparison to control untreated cells. 
The combination index (CI) was calculated for each 
combination according to Chou [50]. For immunoblot 
assays, the MDA-MB-231 cells were treated with 1 
µM Erk5i alone, 2 nM of Hsp90i alone, chemotherapy 
alone (2.5 nM docetaxel and 10 nM doxorubicin) or the 
combinations. After 24 hours of treatments, lysates were 
prepared and standard immunobloting was performed. For 
ex vivo studies, tumors excised from mice on day 13 (after 
treatment completion) were bisected where one half was 
fixed in 10% saline-buffered formalin solution and the 
second half was used to prepare protein lysates.
Standard immunoblots were performed on lysates 
from cells grown in vitro and from tumors excised after 
treatments. The rabbit polyclonal antibodies against Erk5, 
phospho-Erk5 (Thr218/Tyr220), Hsp70, Hsp90, Erk1/2 
and phosphor-Erk1/2 (Thr202/Tyr204) were purchased 
from Cell Signaling (MA, USA). The rabbit monoclonal 
antibodies against Bak and Bim were from Epitomics (CA, 
USA). The mouse monoclonal antibodies against Bcl-xL 
and β-actin were from BD Biosciences (CA, USA). The 
rabbit monoclonal antibody against COXIV was purchased 
from LI-COR Biosciences (NE, USA). Secondary 
antibodies against mouse and rabbit IgG conjugated to 
HRP were from Cell Signaling and blots were developed 
using developed using the chemiluminescence reagent 
plus (Millipore, MA, USA). 
Formalin fixed, paraffin embedded tumors were 
used for standard H&E or Masson’s trichrome staining. 
Immunohistochemical staining (IHC) was performed to 
detect double strand DNA breaks (DSBs) using the anti-
phospho-histone H2AX (Ser139, γH2AX) mAb (clone 
JBW301, Merk Millipore. MA, USA) or apoptosis using 
ApopTag® Peroxidase In Situ Apoptosis Detection Kit 
(Merk Millipore) as per manufacturer instructions. For 
IHC quantification, images of ten random regions from 
each tumor section were analyzed using ImageJ [51] 
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(V1.46d) with ImmunoRatio plugin [52]. Masson’s 
trichrome was analyzed using ImageJ as previously 
described [53] using images of ten random regions 
from each tumor section. Standard immunoblotting was 
performed using lysates prepared from freshly isolated 
tumors.
Statistical analysis
Statistical analysis of the KinexTM antibody arrays 
was performed in ArrayTools as described above. Other 
statistical analyses were performed in GraphPad Prism®.
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